초록

The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.

대표청구항 ▼

What is claimed is: 1. A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, blocks ligand activation of an ErbB receptor more effectively than humanized monoclonal antibody huM

What is claimed is: 1. A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, blocks ligand activation of an ErbB receptor more effectively than humanized monoclonal antibody huMAb4D5-8 and blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB12697) to ErbB2. 2. The method of claim 1 wherein the antibody blocks TGF-α activation of mitogen-activated protein kinase (MAPK). 3. The method of claim 1 wherein the antibody blocks formation of an ErbB hetero-oligomer. 4. The method of claim 1 wherein the antibody comprises monoclonal antibody 2C4 (ATCC HB12697) or a humanized form thereof that binds to the same epitope as the monoclonal antibody 2C4 (ATCC HB12697). 5. The method of claim 1 wherein the antibody is an antibody fragment. 6. The method of claim 5 wherein the antibody fragment is a Fab fragment. 7. The method of claim 5 wherein the antibody fragment is not conjugated with a cytotoxic agent. 8. The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent. 9. A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, blocks ligand activation of an ErbB receptor, blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB12697) to ErbB2, and blocks TGF-α activation of mitogen activated protein kinase (MAPK). 10. The method of claim 9 wherein the antibody comprises monoclonal antibody 2C4 (ATCC HB12697) or a humanized form thereof that binds to the same epitope as the monoclonal antibody 2C4 (ATCC HB12697). 11. The method of claim 9 wherein the antibody is an antibody fragment. 12. The method of claim 11 wherein the antibody fragment is a Fab fragment. 13. The method of claim 11 wherein the antibody fragment is not conjugated with a cytotoxic agent. 14. The method of claim 9 wherein the antibody is not conjugated with a cytotoxic agent.